Grupo Biotoscana 
Welcome,         Profile    Billing    Logout  
 4 Products   161 Diseases  4 Products   147 Trials   1855 News 
63 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fycompa (perampanel) / Eisai, Catalyst Pharma
NCT03653741: Effects of Perampanel on Neurophysiology Test Perimeters

Completed
4
12
US
Perampanel 6 MG, perampanel
Weill Medical College of Cornell University, Eisai Inc.
Healthy
11/21
11/21
ChiCTR2100051885: Efficacy, safety and pharmacokinetics/pharmacodynamics of perampanel in the treatment of epileptic seizures

Recruiting
4
100
 
parempanel additive therapy
Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, Research Fund for AMPA Mechanism and Antiepileptic Drug Research
epilepsy
 
 
NCT04118829: Correlation of Serum Level of Perampanel (PER) Level to Cerebrospinal Fluid (CSF) Levels of PER

Recruiting
4
25
US
Perampanel
Carilion Clinic
Epilepsy, Seizures
09/22
03/23
ChiCTR2000039510: A multi-center, open clinical trial to evaluate the effectiveness and safety of perampanel as an early add-on treatment for partial seizure

Recruiting
4
300
 
Perampanel tablets
Xuanwu Hospital of Capital Medical University; China Association Against Epilepsy, CAAE, Eisai (China) Pharmaceutical Co., Ltd.
Epilepsy
 
 
NCT04650204: Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

Terminated
4
4
US
Anticonvulsant Agent, Anti-seizure agent, anticonvulsant, Anticonvulsant Agents, Anticonvulsants, antiepileptic, Antiepileptic Agent, Antiepileptics, Perampanel, E2007, Fycompa, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Mayo Clinic, National Cancer Institute (NCI)
Intractable Epilepsy, Malignant Glioma, Seizure Disorder, WHO Grade 2 Glioma, WHO Grade 3 Glioma
04/23
04/23
ChiCTR2300074575: A single-center，observational cohort study to evaluate the effectiveness and safety of perampanel monotherapy in adults with focal seizures

Completed
4
70
 
None
Nanjing Brain Hospital; Nanjing Brain Hospital, None
epilepsy
 
 
NCT04417907: Perampanel Titration and Cognitive Effects

Terminated
4
29
US
Perampanel 1 week titration, Fycompa, Perampanel 2 week titration, Perampanel 4mg, Placebo
Kimford Jay Meador, Eisai Inc.
Epilepsy
05/23
05/23
NCT05201703: Fycompa in Catamenial Epilepsy

Terminated
4
7
US
Fycompa, Perampanel, Fycompa with a boost
University of Florida, Eisai Inc.
Catamenial Epilepsy
12/23
12/23
ChiCTR2200055423: A clinical trial study on the effect of perampanel on the prognosis of patients with traumatic brain injury

Recruiting
4
200
 
Placebo ;Perampanel treatment
The 904th Hospital of PLA; The 904th Hospital of PLA, Municipal Health Commission of Wuxi
Traumatic brain injury
 
 
ChiCTR2200066392: A Real World Multicenter Study of Perampanel Monotherapy in Children with Epilepsy

Not yet recruiting
4
420
 
PER monotherapy
Guangzhou Women and Children's Medical Center; Guangdong Provincial People's Hospital, Nil
epilepsy
 
 
ChiCTR2300068059: To evaluate the efficacy and safety of perampanel monotherapy in the treatment of newly diagnosed children with focal epilepsy in China in a real-world setting

Recruiting
4
210
 
Pirentanil, once a day
Peking University First Hospital; Peking University First Hospital, Eisai (China) Pharmaceutical Co., Ltd.
Focal epilepsy
 
 
NCT05533814: A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures

Completed
4
125
RoW
Perampanel, Fycompa, E2007
Eisai Korea Inc.
Epilepsy
01/25
01/25
ChiCTR2300076947: A single-center, prospective, observational real-world study of Perampanel treatment in children aged 4-18 years with epilepsy

Recruiting
4
100
 
Department of Pediatrics, the First Affiliated Hospital of Fujian Medical University; Department of Pediatrics, the First Affiliated Hospital of Fujian Medical University, None
Epilepsy
 
 
NCT05684978: Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus

Not yet recruiting
4
25
US
Perampanel, Fycompa
Wayne State University
Refractory Status Epilepticus
12/27
01/28
2019-000882-19: Efficacy of add-on PEramPanel in focal motor Status epilepticus Efficacité du PEramPanel (PER) dans le traitement de l'état de mal épileptique focal moteur

Not yet recruiting
3
332
Europe
Fycompa, Film-coated tablet, Fycompa
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), Ministère des Solidarités et de la Santé
Patients with a focal motor status epilepticus Patients présentant un état de mal épileptique focal moteur, NA NA, Diseases [C] - Nervous System Diseases [C10]
 
 
PEPSI, NCT04309721: Perampanel in Focal Status Epilepticus

Terminated
3
1
Europe
Perampanel, Experimental group, Placebo, Control group
Assistance Publique - Hôpitaux de Paris
Epilepticus; Status, Focal Motor
11/22
11/23
2021-001839-77: Efficacy and saefety of Perampanel on behaviour and quality of life in Patients with POGZ-Related Disorder Efficacia e sicurezza del Perampanel sul comportamento e la qualità di vita nei pazienti con sindrome POGZ

Not yet recruiting
2
40
Europe
Fycompa, perampanel, [042581037], [n.a.], Coated tablet
IRCCS MATERNO INFANTILE BURLO GAROFOLO, IRCCS materno infantile Burlo Garofolo
Patients with POGZ related disorder Pazienti con varianti patogenetiche/verosimilmente patogenetiche nel gene POGZ, Patients with neurodevelopmental disorder characterized by intellectual disability and/or autism and malformations in different organs of genetic origin Pazienti con disordini del neurosviluppo caratterizzato da disabilità intellettiva e/o autismo e malformazioni in vari organi di origine monogenica, Diseases [C] - Symptoms and general pathology [C23]
 
 
NCT02914314 / 2013-005391-17: Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy

Completed
2
26
Europe, US
perampanel, E2007
Eisai Inc.
Epilepsy
08/22
04/23
PROSPER, NCT06401707: PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest

Recruiting
2
52
US
Perampanel, Fycompa, Placebo
University of California, San Francisco
Heart Arrest, Seizures, Status Epilepticus
05/26
10/26
ACTRN12618001984280: Perampanel for the prevention of post-stroke epilepsy- efficacy and safety

Active, not recruiting
2
164
 
Alfred Health, Alfred Health
Stroke, Epilepsy
 
 
NCT04015141 / 2018-004456-38: A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Recruiting
2
100
Europe, US, RoW
Perampanel Oral Suspension, E2007, Fycompa, Perampanel Tablet
Eisai Inc.
Pediatric Epileptic Syndrome, Partial-onset Seizures
04/27
12/27
NCT05786066: The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

Recruiting
2
30
US
Perampanel 6 MG, Ketamine, Placebo
Yale University, American Foundation for Suicide Prevention, National Center for PTSD, VA Connecticut Healthcare System
Depressive Disorder, Major Depressive Disorder, Bipolar Disorder, Post Traumatic Stress Disorder, Suicidal Ideation
03/33
03/33
NCT04497142: Effect of Perampanel on Peritumoral Hyperexcitability in HGG

Completed
1/2
12
US
Perampanel, E2007, Fycompa, Standard of Care, Standard treatment (typically the anti-seizure medication levetiracetam)
Dana-Farber Cancer Institute, National Cancer Institute (NCI), Eisai Inc.
Glioma, Malignant, Surgery, Seizures
05/23
05/23
NCT03367533: Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial

Completed
1
13
US
Ketamine, Perampanel, Placebo
Yale University, National Institute of Mental Health (NIMH)
Depressive Disorder, Major, Post Traumatic Stress Disorder, Bipolar Disorder
07/22
07/22
NCT06450223: Bioequivalence Study of Perampanel Tablets 12 mg

Completed
1
30
RoW
Perampanel 12 MG, Fycompa 12 mg film-coated tablets
Humanis Saglık Anonim Sirketi
Epilepsy
09/23
12/23
NCT06450236: Bioequivalence Study of Perampanel Tablets 10 mg

Completed
1
30
RoW
Perampanel 10 MG, Fycompa 10Mg Tablet
Humanis Saglık Anonim Sirketi
Epilepsy
11/23
02/24
NCT06969963: Bioequivalence Assessment Between Two Perampanel Oral Suspension Formulations

Completed
1
26
RoW
Lepsiramp, 0.5 Mg/mL Oral Suspension, Perampanel 0.5mg/mL, Fycompa, 0.5 Mg/mL Oral Suspension, perampanel 0.5mg/mL
Aya Mohammed Abdel Magid Abdel Hamid, Advanced Research Center (ARC), Global Napi Pharmaceuticals for Global Advanced Pharmaceuticals
Bioequivalence Study in Healthy Subjects
07/24
07/24
NCT05915013: Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

Recruiting
1
50
US
Ketamine, Perampanel, Placebo
Yale University, National Institute of Mental Health (NIMH)
Depressive Disorder, Major, Post Traumatic Stress Disorder
12/32
12/32
NCT01871233: An Extended Access Program for Perampanel

No Longer Available
N/A
Europe, Canada, RoW
Perampanel, E2007
Eisai Inc.
Partial Onset Seizures
 
 
NCT05274035: A Multi-center RWS of Perampanel as an add-on Treatment for Epileptic Seizures in Chinese Children

Active, not recruiting
N/A
1000
RoW
Perampanel, Fycompa
Beijing Children's Hospital
Epilepsy
11/21
07/22
ChiCTR2300074696: A real-world multicenter clinical study of perampanel as adjunctive treatment in children with epilepsy in China

Completed
N/A
70
 
None
Department of Neurology,Wuhan Children's Hospital of Tongji Medical College,Huazhong University of Science and Technology; WuHan Children's Hospital, Construction Project of Clinical Medical Research Center for Neurodevelopmental Disabilities in Children in Hubei Province(No.HST2020-19)
epilepsy
 
 
NCT04252846: A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

Completed
N/A
191
Europe, RoW
Perampanel, Fycompa
Eisai Limited
Idiopathic Generalized Epilepsy, Partial Onset Seizures, Generalised Tonic-Clonic Seizures
01/23
01/23
NCT03020797: A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Terminated
N/A
12
US
Perampanel, Fycompa, Placebo Oral Tablet
Stony Brook University, Eisai Inc.
Amyotrophic Lateral Sclerosis
01/23
02/23
NCT04202159: A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures

Completed
N/A
187
Europe
Perampanel, E2007, Fycompa
Eisai GmbH
Seizures
03/23
03/23
NCT02307578: An Extended Access Program (EAP) for Perampanel

Available
N/A
Europe, RoW
Perampanel, E2007, Fycompa
Eisai Inc.
Primary Generalized Tonic-Clonic or Partial Onset Seizures, Lennox Gastaut Syndrome
 
 
NCT04858841: Post-stroke Epilepsy: Primary Prophylaxis Study

Recruiting
N/A
180
RoW
Levetiracetam Oral Product, keppra, Perampanel Oral Product, fycompa, Placebo
National Cheng Kung University, Ministry of Science and Technology, Taiwan, National Cheng-Kung University Hospital
Middle Cerebral Artery Stroke
07/23
07/23
SUPER-CAT, NCT05756621: Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest

Recruiting
N/A
80
Europe
Ketamine, Perampanel, Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel, Levetiracetam, Valproate, Phenytoin, Lacosamide, Topiramate, Propofol, Midazolam, Thiopental
University of Milano Bicocca, Azienda Ospedaliera San Gerardo di Monza, Azienda Ospedaliero-Universitaria di Modena, Azienda Ospedaliera Universitaria Integrata Verona, Ospedale Centrale Bolzano, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Azienda Ospedaliero-Universitaria Careggi, Azienda Ospedaliero-Universitaria di Parma, Santa Chiara Hospital, Ospedale M. Bufalini Cesena, Azienda Ospedaliera Brotzu, Istituto Di Ricerche Farmacologiche Mario Negri
Status Epilepticus, Cardiac Arrest
03/25
03/25
ChiCTR2300070693: Pharmacokinetics and Bioequivalence study of perampanel oral suspension in healthy Chinese volunteers

Recruiting
N/A
74
 
Fed condition: the test formulation was given in the first period, and reference formulation was given in the second period ;Fed condition: the reference formulation was given in the first period, and test formulation was given in the second period ;Fasting condition: the test formulation was given in the first period, and reference formulation was given in the second period ;Fasting condition: the reference formulation was given in the first period, and test formulation was given in the second period
Deyang People's Hospital; Jiangxi Kerui Pharmaceutical Co., Ltd, Jiangxi Kerui Pharmaceutical Co., Ltd
Partial seizure of epilepsy
 
 
ChiCTR2200059080: A randomized, controlled, multicenter clinical study evaluating the efficacy and safety of perampanel versus levetiracetam monotherapy in newly diagnosed focal epilepsy greater than or equal to 12 years of age

Not yet recruiting
N/A
200
 
Oral perampanel ;Oral Levetiracetam
The Seventh Affiliated Hospital, Sun Yat-Sen University; The Seventh Affiliated Hospital, Sun Yat-Sen University, China Association Against Epilepsy
Epilepsy
 
 
ChiCTR2300072371: Clinical trial of perampanel in the treatment of paroxysmal kinesigenic dyskinesia

Not yet recruiting
N/A
40
 
perampanel ;oxcarbazepine
Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, self-raised
paroxysmal kinesigenic dyskinesia
 
 
NCT06657378: A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures

Recruiting
N/A
110
Japan
No Intervention
Eisai Co., Ltd.
Partial-Onset Seizures, Primary Generalized Tonic-clonic Seizures
06/28
06/28
EPIPOP, NCT03196466: Population Pharmacokinetics of Antiepileptic in Pediatrics

Recruiting
N/A
1000
Europe
Valproic acid, carbamazepine, phenobarbital, phenytoin, levetiracetam, lamotrigine, topiramate, oxcarbazepine, stiripentol, clobazam, brivaracétam, felbamate, lacosamide, rufinamide, gabapentine, pregabaline, sultiame, tiagabine, vigabatrine, mesuximide, primidone, perampanel, ethosuximide, zonisamide, cannabidiol, genetic polymorphisms
Assistance Publique - Hôpitaux de Paris
Epilepsy
06/26
06/26
NCT05257915: A China RWS to Evaluate the Effectiveness and Safety of Perampanel as an add-on Treatment for Epileptic Seizure

Active, not recruiting
N/A
600
RoW
Perampanel, Fycompa
Beijing Children's Hospital
Epilepsy
10/21
06/22
NCT05497193: Clinical Efficacy and Safety of Perampanel Monotherapy in the Treatment of Children With Focal Epilepsy

Active, not recruiting
N/A
280
RoW
perampanel, No other interventions currently
Yang Xinwei
Focal Epilepsy
03/23
10/23
Cresemba (isavuconazonium sulfate) / Astellas, Basilea
2019-004240-30: CLINICAL TRIAL TO ANALYZE THE BRONCHOPULMONARY PENETRANCE OF ISAVUCONAZOLE IN PULMONARY TRANSPLANT RECIPIENTS PATIENTS ENSAYO CLÍNICO PARA ANALIZAR LA PENETRANCIA BRONCOPULMONAR DE ISAVUCONAZOL EN PACIENTES RECEPTORES DE TRASPLANTE PULMONAR

Ongoing
4
12
Europe
CRESEMBA, Capsule, CRESEMBA
FUNDACIÓN PARA LA INVESTIGACION BIOMEDICA HU PUERTA DE HIERRO MAJADAHONDA, PNEUMOLOGY DEPARTMENT (HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA)
Lung transplant recipients with a diagnosis of invasive fungal disease Pacientes receptores de trasplante pulmonar con diagnóstico de enfermedad fúngica invasiva., Patients with lung transplantation with invasive fungal infection Pacientes con trasplante pulmonar con infección invasiva por hongos, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2017-001433-74: Screening Anti-Fungal Exposure in Intensive Care Units – The French Cohort

Completed
4
40
Europe
Powder for concentrate for dispersion for infusion, Powder for solution for infusion, AmBisome Liposomal Amphotericin B 50mg Powder for Concentrate for Dispersion for Infusion., ECALTA 100 mg powder for concentrate for solution for infusion, CANCIDAS 50 mg powder for concentrate for solution for infusion, Diflucan 150 mg hard capsules, CRESEMBA 200 mg powder for concentrate for solution for infusion, Mycamine 50 mg powder for solution for infusion, Noxafil® 300 mg concentrate for solution for infusion, Voriconazole 200 mg powder for solution for infusion
CHU de NIMES, CHU NIMES
The study will recruit patients in intensive care unit prescribed to receive any of the chosen systemic antifungal agents, The study will recruit patients in intensive care unit prescribed to receive any of the chosen systemic antifungal agents, Not possible to specify
 
 
NCT06756191: Antifungal Drugs in Pulmonary Mucormycosis

Not yet recruiting
4
312
NA
Combination therapy group, Liposomal Amphotericin B
Bin Cao
Pulmonary Mucormycosis
07/25
12/26
NCT05630976: Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi

Active, not recruiting
4
35
RoW
Isavuconazole, Cresemba®
Pfizer
Invasive Fungal Disease
04/25
04/25
ChiCTR2500095746: Efficacy and Safety of Liposomal Amphotericin B (AmBisome ) Plus Isavuconazole Versus AmBisome in the Management of Pulmonary Mucormycosis: A multicenter, Prospective, Open Label, Randomized Controlled Study

Not yet recruiting
4
312
 
Liposomal Amphotericin B (AmBisome) Plus Isavuconazole; Liposomal Amphotericin B (AmBisome)
China-Japan Friendship Hospital; China-Japan Friendship Hospital, self funded
Pulmonary mucormycosis
 
 
2019-002569-37: Empirical steroids and/or antifungals treatment in patient with immunodeficiency experiencing acute respiratory failure from undetermined origin a multicenter double-blind randomized controlled trial Impact d’un traitement empirique par stéroïdes et/ou antifongiques sur la mortalité des patients immunodéprimés avec insuffisance respiratoire aiguë d'origine indéterminée.

Not yet recruiting
3
420
Europe
ISAVUCONAZOLE, METHYLPREDNISOLONE, Powder for infusion, Powder for solution for infusion, CRESEMBA
Assistance Publique Hôpitaux de Paris, AP-HP
immunocompromised patients with acute respiratory failure patients immunodéprimés avec insuffisance respiratoire aiguë, immunocompromised patients with acute respiratory failure patients immunodéprimés avec insuffisance respiratoire aiguë, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
 
 
IA-DUET, NCT04876716 / 2020-000627-40: Azole-echinocandin Combination Therapy for Invasive Aspergillosis

Terminated
3
66
Europe
Azole, Voriconazole, isavuconazole, posaconazole, Anidulafungin, Ecalta
Erasmus Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Stichting Hemato-Oncologie voor Volwassenen Nederland
Invasive Aspergillosis
05/24
05/24
2016-003921-40: Open label study of the efficacy and safety of isavuconazole for the treatment of Chronic Pulmonary Aspergillosis

Not yet recruiting
2
20
Europe
Cresemba 100 mg hard capsules, Capsule, hard, Cresemba 100 mg hard capsules
University Hospital of South Manchester NHS Foundation Trust
Chronic Pulmonary Aspergillosis, Chronic chest infection caused by fungus species Aspergillus., Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
19-C-0103, NCT03964090: Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

Active, not recruiting
2
48
US
TEDD-R, TEDDI-R, Ibrutinib, Cytarabine, Isavuconazole, Methotrexate
National Cancer Institute (NCI)
Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
07/25
07/26
NCT04548648: A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas

Active, not recruiting
2
10
US
Acalabrutinib, ACP-196, CALQUENCE
UNC Lineberger Comprehensive Cancer Center, AstraZeneca
Central Nervous System Lymphoma
05/25
03/30
NCT02203526: Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

Recruiting
1
93
US
Isavuconazole, TEDDI, Rituximab, Cytarabine, TEDD, Ibrutinib (Arms 2, 3 and 4), Methotrexate, Ibrutinib (Arm 1 - Closed with Amendment G), Ibrutinib (Arm 4)
National Cancer Institute (NCI)
Primary Central Nervous System Lymphoma
06/25
06/27
PRISMA, NCT04550936: Patterns of Real-World Isavuconazole Use - a Study of Patients With Mucormycosis or Invasive Aspergillosis

Completed
N/A
307
Europe
Isavuconazole, Cresemba
Pfizer
Invasive Aspergillosis, Mucormycosis
12/23
12/23
ESCAI, NCT04486885: European Study of Cerebral Aspergillosis Treated With Isavuconazole

Completed
N/A
41
Europe
Imagine Institute
Cerebral Aspergillosis, Invasive Aspergillosis
08/22
03/23
NCT06440915: Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children

Recruiting
N/A
200
RoW
Theraputic drug monitoring, Isavuconazole
Shanghai Children's Medical Center
Aspergillosis Invasive, Mucormycosis
06/26
06/26
NCT06495905: Efficacy and Safety of Systematic Therapy and Bronchoscopic Interventional Treatment for Pulmonary Mucormycosis

Enrolling by invitation
N/A
30
RoW
transbronchoscopic interventional debridement, transbronchoscopic local precision infusion of amphotericin B, transoral nebulized inhalation of amphotericin B, liposomal amphotericin B + posaconazole or Isavuconazole
Beijing Tsinghua Chang Gung Hospital
Pulmonary Mucormycosis
07/25
12/25
NCT04744454: Post Marketing Surveillance (PMS) Study of Cresemba in Korea.

Recruiting
N/A
600
RoW
Isauvuconazole group
Pfizer
Aspergillosis, Mucormycosis
01/26
01/26
ChiCTR2400086245: Study on theraputic drug monitoring and phamacokinetics of isavuconazole in children

Not yet recruiting
N/A
200
 
Isavuconazole
Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University; Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Self-financed Programs
Invasive aspergillosis and Invasive mucormycosis
 
 
ChiCTR2500097739: Comprehensive Clinical Evaluation of Domestic Isavuconazole in the Treatment of Invasive Aspergillosis and Invasive Mucormycosis

Not yet recruiting
N/A
60
 
None; None
Northern Jiangsu People's Hospital; Northern Jiangsu People's Hospital, The Pharmaceutical Society of Jiangsu Province
Invasive aspergillosis and invasive mucormycosis
 
 
NCT05426499: Translational PKPD Modeling of Anti-infective Drugs Used in Pediatric Units.

Recruiting
N/A
150
Europe
Patients requiring cefotaxime treatment, Patients requiring meropenem treatment, Patients requiring fluconazole treatment, Patients requiring isavuconazole treatment, Patients requiring anidulafungin treatment
Poznan University of Medical Sciences, University at Buffalo, The Greater Poland Cancer Centre
Population Modeling of Anti-infective Drugs
06/25
09/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fycompa (perampanel) / Eisai, Catalyst Pharma
NCT03653741: Effects of Perampanel on Neurophysiology Test Perimeters

Completed
4
12
US
Perampanel 6 MG, perampanel
Weill Medical College of Cornell University, Eisai Inc.
Healthy
11/21
11/21
ChiCTR2100051885: Efficacy, safety and pharmacokinetics/pharmacodynamics of perampanel in the treatment of epileptic seizures

Recruiting
4
100
 
parempanel additive therapy
Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, Research Fund for AMPA Mechanism and Antiepileptic Drug Research
epilepsy
 
 
NCT04118829: Correlation of Serum Level of Perampanel (PER) Level to Cerebrospinal Fluid (CSF) Levels of PER

Recruiting
4
25
US
Perampanel
Carilion Clinic
Epilepsy, Seizures
09/22
03/23
ChiCTR2000039510: A multi-center, open clinical trial to evaluate the effectiveness and safety of perampanel as an early add-on treatment for partial seizure

Recruiting
4
300
 
Perampanel tablets
Xuanwu Hospital of Capital Medical University; China Association Against Epilepsy, CAAE, Eisai (China) Pharmaceutical Co., Ltd.
Epilepsy
 
 
NCT04650204: Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

Terminated
4
4
US
Anticonvulsant Agent, Anti-seizure agent, anticonvulsant, Anticonvulsant Agents, Anticonvulsants, antiepileptic, Antiepileptic Agent, Antiepileptics, Perampanel, E2007, Fycompa, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Mayo Clinic, National Cancer Institute (NCI)
Intractable Epilepsy, Malignant Glioma, Seizure Disorder, WHO Grade 2 Glioma, WHO Grade 3 Glioma
04/23
04/23
ChiCTR2300074575: A single-center，observational cohort study to evaluate the effectiveness and safety of perampanel monotherapy in adults with focal seizures

Completed
4
70
 
None
Nanjing Brain Hospital; Nanjing Brain Hospital, None
epilepsy
 
 
NCT04417907: Perampanel Titration and Cognitive Effects

Terminated
4
29
US
Perampanel 1 week titration, Fycompa, Perampanel 2 week titration, Perampanel 4mg, Placebo
Kimford Jay Meador, Eisai Inc.
Epilepsy
05/23
05/23
NCT05201703: Fycompa in Catamenial Epilepsy

Terminated
4
7
US
Fycompa, Perampanel, Fycompa with a boost
University of Florida, Eisai Inc.
Catamenial Epilepsy
12/23
12/23
ChiCTR2200055423: A clinical trial study on the effect of perampanel on the prognosis of patients with traumatic brain injury

Recruiting
4
200
 
Placebo ;Perampanel treatment
The 904th Hospital of PLA; The 904th Hospital of PLA, Municipal Health Commission of Wuxi
Traumatic brain injury
 
 
ChiCTR2200066392: A Real World Multicenter Study of Perampanel Monotherapy in Children with Epilepsy

Not yet recruiting
4
420
 
PER monotherapy
Guangzhou Women and Children's Medical Center; Guangdong Provincial People's Hospital, Nil
epilepsy
 
 
ChiCTR2300068059: To evaluate the efficacy and safety of perampanel monotherapy in the treatment of newly diagnosed children with focal epilepsy in China in a real-world setting

Recruiting
4
210
 
Pirentanil, once a day
Peking University First Hospital; Peking University First Hospital, Eisai (China) Pharmaceutical Co., Ltd.
Focal epilepsy
 
 
NCT05533814: A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures

Completed
4
125
RoW
Perampanel, Fycompa, E2007
Eisai Korea Inc.
Epilepsy
01/25
01/25
ChiCTR2300076947: A single-center, prospective, observational real-world study of Perampanel treatment in children aged 4-18 years with epilepsy

Recruiting
4
100
 
Department of Pediatrics, the First Affiliated Hospital of Fujian Medical University; Department of Pediatrics, the First Affiliated Hospital of Fujian Medical University, None
Epilepsy
 
 
NCT05684978: Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus

Not yet recruiting
4
25
US
Perampanel, Fycompa
Wayne State University
Refractory Status Epilepticus
12/27
01/28
2019-000882-19: Efficacy of add-on PEramPanel in focal motor Status epilepticus Efficacité du PEramPanel (PER) dans le traitement de l'état de mal épileptique focal moteur

Not yet recruiting
3
332
Europe
Fycompa, Film-coated tablet, Fycompa
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), Ministère des Solidarités et de la Santé
Patients with a focal motor status epilepticus Patients présentant un état de mal épileptique focal moteur, NA NA, Diseases [C] - Nervous System Diseases [C10]
 
 
PEPSI, NCT04309721: Perampanel in Focal Status Epilepticus

Terminated
3
1
Europe
Perampanel, Experimental group, Placebo, Control group
Assistance Publique - Hôpitaux de Paris
Epilepticus; Status, Focal Motor
11/22
11/23
2021-001839-77: Efficacy and saefety of Perampanel on behaviour and quality of life in Patients with POGZ-Related Disorder Efficacia e sicurezza del Perampanel sul comportamento e la qualità di vita nei pazienti con sindrome POGZ

Not yet recruiting
2
40
Europe
Fycompa, perampanel, [042581037], [n.a.], Coated tablet
IRCCS MATERNO INFANTILE BURLO GAROFOLO, IRCCS materno infantile Burlo Garofolo
Patients with POGZ related disorder Pazienti con varianti patogenetiche/verosimilmente patogenetiche nel gene POGZ, Patients with neurodevelopmental disorder characterized by intellectual disability and/or autism and malformations in different organs of genetic origin Pazienti con disordini del neurosviluppo caratterizzato da disabilità intellettiva e/o autismo e malformazioni in vari organi di origine monogenica, Diseases [C] - Symptoms and general pathology [C23]
 
 
NCT02914314 / 2013-005391-17: Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy

Completed
2
26
Europe, US
perampanel, E2007
Eisai Inc.
Epilepsy
08/22
04/23
PROSPER, NCT06401707: PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest

Recruiting
2
52
US
Perampanel, Fycompa, Placebo
University of California, San Francisco
Heart Arrest, Seizures, Status Epilepticus
05/26
10/26
ACTRN12618001984280: Perampanel for the prevention of post-stroke epilepsy- efficacy and safety

Active, not recruiting
2
164
 
Alfred Health, Alfred Health
Stroke, Epilepsy
 
 
NCT04015141 / 2018-004456-38: A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Recruiting
2
100
Europe, US, RoW
Perampanel Oral Suspension, E2007, Fycompa, Perampanel Tablet
Eisai Inc.
Pediatric Epileptic Syndrome, Partial-onset Seizures
04/27
12/27
NCT05786066: The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

Recruiting
2
30
US
Perampanel 6 MG, Ketamine, Placebo
Yale University, American Foundation for Suicide Prevention, National Center for PTSD, VA Connecticut Healthcare System
Depressive Disorder, Major Depressive Disorder, Bipolar Disorder, Post Traumatic Stress Disorder, Suicidal Ideation
03/33
03/33
NCT04497142: Effect of Perampanel on Peritumoral Hyperexcitability in HGG

Completed
1/2
12
US
Perampanel, E2007, Fycompa, Standard of Care, Standard treatment (typically the anti-seizure medication levetiracetam)
Dana-Farber Cancer Institute, National Cancer Institute (NCI), Eisai Inc.
Glioma, Malignant, Surgery, Seizures
05/23
05/23
NCT03367533: Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial

Completed
1
13
US
Ketamine, Perampanel, Placebo
Yale University, National Institute of Mental Health (NIMH)
Depressive Disorder, Major, Post Traumatic Stress Disorder, Bipolar Disorder
07/22
07/22
NCT06450223: Bioequivalence Study of Perampanel Tablets 12 mg

Completed
1
30
RoW
Perampanel 12 MG, Fycompa 12 mg film-coated tablets
Humanis Saglık Anonim Sirketi
Epilepsy
09/23
12/23
NCT06450236: Bioequivalence Study of Perampanel Tablets 10 mg

Completed
1
30
RoW
Perampanel 10 MG, Fycompa 10Mg Tablet
Humanis Saglık Anonim Sirketi
Epilepsy
11/23
02/24
NCT06969963: Bioequivalence Assessment Between Two Perampanel Oral Suspension Formulations

Completed
1
26
RoW
Lepsiramp, 0.5 Mg/mL Oral Suspension, Perampanel 0.5mg/mL, Fycompa, 0.5 Mg/mL Oral Suspension, perampanel 0.5mg/mL
Aya Mohammed Abdel Magid Abdel Hamid, Advanced Research Center (ARC), Global Napi Pharmaceuticals for Global Advanced Pharmaceuticals
Bioequivalence Study in Healthy Subjects
07/24
07/24
NCT05915013: Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

Recruiting
1
50
US
Ketamine, Perampanel, Placebo
Yale University, National Institute of Mental Health (NIMH)
Depressive Disorder, Major, Post Traumatic Stress Disorder
12/32
12/32
NCT01871233: An Extended Access Program for Perampanel

No Longer Available
N/A
Europe, Canada, RoW
Perampanel, E2007
Eisai Inc.
Partial Onset Seizures
 
 
NCT05274035: A Multi-center RWS of Perampanel as an add-on Treatment for Epileptic Seizures in Chinese Children

Active, not recruiting
N/A
1000
RoW
Perampanel, Fycompa
Beijing Children's Hospital
Epilepsy
11/21
07/22
ChiCTR2300074696: A real-world multicenter clinical study of perampanel as adjunctive treatment in children with epilepsy in China

Completed
N/A
70
 
None
Department of Neurology,Wuhan Children's Hospital of Tongji Medical College,Huazhong University of Science and Technology; WuHan Children's Hospital, Construction Project of Clinical Medical Research Center for Neurodevelopmental Disabilities in Children in Hubei Province(No.HST2020-19)
epilepsy
 
 
NCT04252846: A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

Completed
N/A
191
Europe, RoW
Perampanel, Fycompa
Eisai Limited
Idiopathic Generalized Epilepsy, Partial Onset Seizures, Generalised Tonic-Clonic Seizures
01/23
01/23
NCT03020797: A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Terminated
N/A
12
US
Perampanel, Fycompa, Placebo Oral Tablet
Stony Brook University, Eisai Inc.
Amyotrophic Lateral Sclerosis
01/23
02/23
NCT04202159: A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures

Completed
N/A
187
Europe
Perampanel, E2007, Fycompa
Eisai GmbH
Seizures
03/23
03/23
NCT02307578: An Extended Access Program (EAP) for Perampanel

Available
N/A
Europe, RoW
Perampanel, E2007, Fycompa
Eisai Inc.
Primary Generalized Tonic-Clonic or Partial Onset Seizures, Lennox Gastaut Syndrome
 
 
NCT04858841: Post-stroke Epilepsy: Primary Prophylaxis Study

Recruiting
N/A
180
RoW
Levetiracetam Oral Product, keppra, Perampanel Oral Product, fycompa, Placebo
National Cheng Kung University, Ministry of Science and Technology, Taiwan, National Cheng-Kung University Hospital
Middle Cerebral Artery Stroke
07/23
07/23
SUPER-CAT, NCT05756621: Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest

Recruiting
N/A
80
Europe
Ketamine, Perampanel, Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel, Levetiracetam, Valproate, Phenytoin, Lacosamide, Topiramate, Propofol, Midazolam, Thiopental
University of Milano Bicocca, Azienda Ospedaliera San Gerardo di Monza, Azienda Ospedaliero-Universitaria di Modena, Azienda Ospedaliera Universitaria Integrata Verona, Ospedale Centrale Bolzano, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Azienda Ospedaliero-Universitaria Careggi, Azienda Ospedaliero-Universitaria di Parma, Santa Chiara Hospital, Ospedale M. Bufalini Cesena, Azienda Ospedaliera Brotzu, Istituto Di Ricerche Farmacologiche Mario Negri
Status Epilepticus, Cardiac Arrest
03/25
03/25
ChiCTR2300070693: Pharmacokinetics and Bioequivalence study of perampanel oral suspension in healthy Chinese volunteers

Recruiting
N/A
74
 
Fed condition: the test formulation was given in the first period, and reference formulation was given in the second period ;Fed condition: the reference formulation was given in the first period, and test formulation was given in the second period ;Fasting condition: the test formulation was given in the first period, and reference formulation was given in the second period ;Fasting condition: the reference formulation was given in the first period, and test formulation was given in the second period
Deyang People's Hospital; Jiangxi Kerui Pharmaceutical Co., Ltd, Jiangxi Kerui Pharmaceutical Co., Ltd
Partial seizure of epilepsy
 
 
ChiCTR2200059080: A randomized, controlled, multicenter clinical study evaluating the efficacy and safety of perampanel versus levetiracetam monotherapy in newly diagnosed focal epilepsy greater than or equal to 12 years of age

Not yet recruiting
N/A
200
 
Oral perampanel ;Oral Levetiracetam
The Seventh Affiliated Hospital, Sun Yat-Sen University; The Seventh Affiliated Hospital, Sun Yat-Sen University, China Association Against Epilepsy
Epilepsy
 
 
ChiCTR2300072371: Clinical trial of perampanel in the treatment of paroxysmal kinesigenic dyskinesia

Not yet recruiting
N/A
40
 
perampanel ;oxcarbazepine
Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, self-raised
paroxysmal kinesigenic dyskinesia
 
 
NCT06657378: A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures

Recruiting
N/A
110
Japan
No Intervention
Eisai Co., Ltd.
Partial-Onset Seizures, Primary Generalized Tonic-clonic Seizures
06/28
06/28
EPIPOP, NCT03196466: Population Pharmacokinetics of Antiepileptic in Pediatrics

Recruiting
N/A
1000
Europe
Valproic acid, carbamazepine, phenobarbital, phenytoin, levetiracetam, lamotrigine, topiramate, oxcarbazepine, stiripentol, clobazam, brivaracétam, felbamate, lacosamide, rufinamide, gabapentine, pregabaline, sultiame, tiagabine, vigabatrine, mesuximide, primidone, perampanel, ethosuximide, zonisamide, cannabidiol, genetic polymorphisms
Assistance Publique - Hôpitaux de Paris
Epilepsy
06/26
06/26
NCT05257915: A China RWS to Evaluate the Effectiveness and Safety of Perampanel as an add-on Treatment for Epileptic Seizure

Active, not recruiting
N/A
600
RoW
Perampanel, Fycompa
Beijing Children's Hospital
Epilepsy
10/21
06/22
NCT05497193: Clinical Efficacy and Safety of Perampanel Monotherapy in the Treatment of Children With Focal Epilepsy

Active, not recruiting
N/A
280
RoW
perampanel, No other interventions currently
Yang Xinwei
Focal Epilepsy
03/23
10/23
Cresemba (isavuconazonium sulfate) / Astellas, Basilea
2019-004240-30: CLINICAL TRIAL TO ANALYZE THE BRONCHOPULMONARY PENETRANCE OF ISAVUCONAZOLE IN PULMONARY TRANSPLANT RECIPIENTS PATIENTS ENSAYO CLÍNICO PARA ANALIZAR LA PENETRANCIA BRONCOPULMONAR DE ISAVUCONAZOL EN PACIENTES RECEPTORES DE TRASPLANTE PULMONAR

Ongoing
4
12
Europe
CRESEMBA, Capsule, CRESEMBA
FUNDACIÓN PARA LA INVESTIGACION BIOMEDICA HU PUERTA DE HIERRO MAJADAHONDA, PNEUMOLOGY DEPARTMENT (HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA)
Lung transplant recipients with a diagnosis of invasive fungal disease Pacientes receptores de trasplante pulmonar con diagnóstico de enfermedad fúngica invasiva., Patients with lung transplantation with invasive fungal infection Pacientes con trasplante pulmonar con infección invasiva por hongos, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2017-001433-74: Screening Anti-Fungal Exposure in Intensive Care Units – The French Cohort

Completed
4
40
Europe
Powder for concentrate for dispersion for infusion, Powder for solution for infusion, AmBisome Liposomal Amphotericin B 50mg Powder for Concentrate for Dispersion for Infusion., ECALTA 100 mg powder for concentrate for solution for infusion, CANCIDAS 50 mg powder for concentrate for solution for infusion, Diflucan 150 mg hard capsules, CRESEMBA 200 mg powder for concentrate for solution for infusion, Mycamine 50 mg powder for solution for infusion, Noxafil® 300 mg concentrate for solution for infusion, Voriconazole 200 mg powder for solution for infusion
CHU de NIMES, CHU NIMES
The study will recruit patients in intensive care unit prescribed to receive any of the chosen systemic antifungal agents, The study will recruit patients in intensive care unit prescribed to receive any of the chosen systemic antifungal agents, Not possible to specify
 
 
NCT06756191: Antifungal Drugs in Pulmonary Mucormycosis

Not yet recruiting
4
312
NA
Combination therapy group, Liposomal Amphotericin B
Bin Cao
Pulmonary Mucormycosis
07/25
12/26
NCT05630976: Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi

Active, not recruiting
4
35
RoW
Isavuconazole, Cresemba®
Pfizer
Invasive Fungal Disease
04/25
04/25
ChiCTR2500095746: Efficacy and Safety of Liposomal Amphotericin B (AmBisome ) Plus Isavuconazole Versus AmBisome in the Management of Pulmonary Mucormycosis: A multicenter, Prospective, Open Label, Randomized Controlled Study

Not yet recruiting
4
312
 
Liposomal Amphotericin B (AmBisome) Plus Isavuconazole; Liposomal Amphotericin B (AmBisome)
China-Japan Friendship Hospital; China-Japan Friendship Hospital, self funded
Pulmonary mucormycosis
 
 
2019-002569-37: Empirical steroids and/or antifungals treatment in patient with immunodeficiency experiencing acute respiratory failure from undetermined origin a multicenter double-blind randomized controlled trial Impact d’un traitement empirique par stéroïdes et/ou antifongiques sur la mortalité des patients immunodéprimés avec insuffisance respiratoire aiguë d'origine indéterminée.

Not yet recruiting
3
420
Europe
ISAVUCONAZOLE, METHYLPREDNISOLONE, Powder for infusion, Powder for solution for infusion, CRESEMBA
Assistance Publique Hôpitaux de Paris, AP-HP
immunocompromised patients with acute respiratory failure patients immunodéprimés avec insuffisance respiratoire aiguë, immunocompromised patients with acute respiratory failure patients immunodéprimés avec insuffisance respiratoire aiguë, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
 
 
IA-DUET, NCT04876716 / 2020-000627-40: Azole-echinocandin Combination Therapy for Invasive Aspergillosis

Terminated
3
66
Europe
Azole, Voriconazole, isavuconazole, posaconazole, Anidulafungin, Ecalta
Erasmus Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Stichting Hemato-Oncologie voor Volwassenen Nederland
Invasive Aspergillosis
05/24
05/24
2016-003921-40: Open label study of the efficacy and safety of isavuconazole for the treatment of Chronic Pulmonary Aspergillosis

Not yet recruiting
2
20
Europe
Cresemba 100 mg hard capsules, Capsule, hard, Cresemba 100 mg hard capsules
University Hospital of South Manchester NHS Foundation Trust
Chronic Pulmonary Aspergillosis, Chronic chest infection caused by fungus species Aspergillus., Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
19-C-0103, NCT03964090: Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

Active, not recruiting
2
48
US
TEDD-R, TEDDI-R, Ibrutinib, Cytarabine, Isavuconazole, Methotrexate
National Cancer Institute (NCI)
Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
07/25
07/26
NCT04548648: A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas

Active, not recruiting
2
10
US
Acalabrutinib, ACP-196, CALQUENCE
UNC Lineberger Comprehensive Cancer Center, AstraZeneca
Central Nervous System Lymphoma
05/25
03/30
NCT02203526: Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

Recruiting
1
93
US
Isavuconazole, TEDDI, Rituximab, Cytarabine, TEDD, Ibrutinib (Arms 2, 3 and 4), Methotrexate, Ibrutinib (Arm 1 - Closed with Amendment G), Ibrutinib (Arm 4)
National Cancer Institute (NCI)
Primary Central Nervous System Lymphoma
06/25
06/27
PRISMA, NCT04550936: Patterns of Real-World Isavuconazole Use - a Study of Patients With Mucormycosis or Invasive Aspergillosis

Completed
N/A
307
Europe
Isavuconazole, Cresemba
Pfizer
Invasive Aspergillosis, Mucormycosis
12/23
12/23
ESCAI, NCT04486885: European Study of Cerebral Aspergillosis Treated With Isavuconazole

Completed
N/A
41
Europe
Imagine Institute
Cerebral Aspergillosis, Invasive Aspergillosis
08/22
03/23
NCT06440915: Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children

Recruiting
N/A
200
RoW
Theraputic drug monitoring, Isavuconazole
Shanghai Children's Medical Center
Aspergillosis Invasive, Mucormycosis
06/26
06/26
NCT06495905: Efficacy and Safety of Systematic Therapy and Bronchoscopic Interventional Treatment for Pulmonary Mucormycosis

Enrolling by invitation
N/A
30
RoW
transbronchoscopic interventional debridement, transbronchoscopic local precision infusion of amphotericin B, transoral nebulized inhalation of amphotericin B, liposomal amphotericin B + posaconazole or Isavuconazole
Beijing Tsinghua Chang Gung Hospital
Pulmonary Mucormycosis
07/25
12/25
NCT04744454: Post Marketing Surveillance (PMS) Study of Cresemba in Korea.

Recruiting
N/A
600
RoW
Isauvuconazole group
Pfizer
Aspergillosis, Mucormycosis
01/26
01/26
ChiCTR2400086245: Study on theraputic drug monitoring and phamacokinetics of isavuconazole in children

Not yet recruiting
N/A
200
 
Isavuconazole
Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University; Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Self-financed Programs
Invasive aspergillosis and Invasive mucormycosis
 
 
ChiCTR2500097739: Comprehensive Clinical Evaluation of Domestic Isavuconazole in the Treatment of Invasive Aspergillosis and Invasive Mucormycosis

Not yet recruiting
N/A
60
 
None; None
Northern Jiangsu People's Hospital; Northern Jiangsu People's Hospital, The Pharmaceutical Society of Jiangsu Province
Invasive aspergillosis and invasive mucormycosis
 
 
NCT05426499: Translational PKPD Modeling of Anti-infective Drugs Used in Pediatric Units.

Recruiting
N/A
150
Europe
Patients requiring cefotaxime treatment, Patients requiring meropenem treatment, Patients requiring fluconazole treatment, Patients requiring isavuconazole treatment, Patients requiring anidulafungin treatment
Poznan University of Medical Sciences, University at Buffalo, The Greater Poland Cancer Centre
Population Modeling of Anti-infective Drugs
06/25
09/25

Download Options